Patents Assigned to Five Prime Therapeutics, Inc.
  • Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
    Publication number: 20200223931
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 16, 2020
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Justin Wong, Maximiliano Vasquez
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10618967
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: April 14, 2020
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Antibodies Binding to ILT4
    Publication number: 20200079848
    Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
    Type: Application
    Filed: July 9, 2019
    Publication date: March 12, 2020
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
  • Anti-FGFR2 Antibodies in Combination with Chemotherapy Agents in Cancer Treatment
    Publication number: 20200079856
    Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
    Type: Application
    Filed: May 15, 2018
    Publication date: March 12, 2020
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
  • Antibodies Binding to VISTA at Acidic pH
    Publication number: 20200055936
    Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
    Type: Application
    Filed: March 13, 2018
    Publication date: February 20, 2020
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
  • Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10562970
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: February 18, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Justin Wong, Maximiliano Vasquez
  • COMBINATION THERAPY FOR CANCER USING ANTI-GITR ANTIBODIES
    Publication number: 20200031944
    Abstract: Provided herein are methods of treating cancer with a combination of an anti glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR)-antibody and an antibody that binds colony stimulating factor 1 receptor (CSF1R) or with a combination of an anti-GITR antibody and an antibody that binds programmed cell death protein 1 (PD-1).
    Type: Application
    Filed: March 29, 2018
    Publication date: January 30, 2020
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Susannah D. Barbee, David Bellovin, Luis Borges
  • Methods of treating lung cancer
    Patent number: 10537611
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 21, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • PSGL-1 Antagonists and Uses Thereof
    Publication number: 20190330364
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Application
    Filed: January 10, 2018
    Publication date: October 31, 2019
    Applicants: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
  • COMBINED ANTI TUMOR THERAPY WITH A GITR AGONIST AND CPG
    Publication number: 20190263919
    Abstract: The present disclosure relates to methods of using glucocorticoid-induced TNFR-related protein (GITR) agonists as anti-tumor agents, for example in combination with CpG oligodeoxynucleotides. A specific antibody, characterized by its CDRs is described as agonist.
    Type: Application
    Filed: June 30, 2017
    Publication date: August 29, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Susan Foy, Thomas Brennan, Danielle Kellar
  • Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
    Publication number: 20190248908
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Application
    Filed: January 24, 2019
    Publication date: August 15, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist
  • CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT
    Publication number: 20190202889
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas BRENNAN, David BELLOVIN, David BUSHA, Barbara SENNINO
  • Anti-CSF1R Antibody and Anti PD-1 Antibody Combination Therapy for Cancer
    Publication number: 20190202921
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Application
    Filed: January 9, 2019
    Publication date: July 4, 2019
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT
    Publication number: 20190194288
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Application
    Filed: March 7, 2019
    Publication date: June 27, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas BRENNAN, David BELLOVIN, David BUSHA, Barbara SENNINO
  • Afucosylated Anti-FGFR2IIIB Antibodies
    Publication number: 20190175730
    Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 13, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
  • NOPE FOR TREATMENT OF PATHOLOGICAL MUSCLE LOSS AND WEAKNESS
    Publication number: 20190125833
    Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
    Type: Application
    Filed: April 24, 2017
    Publication date: May 2, 2019
    Applicants: Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
  • CD80 extracellular domain polypeptides and their use in cancer treatment
    Patent number: 10273281
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: April 30, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • Anti-CSF1R Antibodies for Treating PVNS
    Publication number: 20190119390
    Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
    Type: Application
    Filed: June 22, 2018
    Publication date: April 25, 2019
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Robert Sikorski, Julie Hambleton, Nilacantan Sankar
  • Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
    Patent number: 10221244
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 5, 2019
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10221243
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: March 5, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist